Clinical trials
SGLT2 Inhibitors clinical trials
Below are recruiting sglt2 inhibitors clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07776054RecruitingPhase 4
SGLT2 inhibitor after heart shock for atrial fibrillation with heart failure
This study tests whether a diabetes drug called an SGLT2 inhibitor can help keep your heart in a normal rhythm after a procedure to shock it back into rhythm. It is for people with persistent atrial fibrillation and a type of heart failure where the heart is stiff.
Seoul, SeoulAges 19 years+ - NCT06668389RecruitingPhase 4
Testing a diabetes medicine for repaired tetralogy of Fallot
This study tests a type of diabetes medicine (SGLT2 inhibitor) to see if it can help people who had surgery for tetralogy of Fallot feel better and have stronger heart and lung function. It may be a good fit if you are an adult with repaired tetralogy of Fallot and do not have certain other health problems.
Hong KongAges 18 years+ - NCT06473844Recruiting
SGLT2 inhibitors for adults with sepsis
This trial tests whether a type of diabetes medicine (SGLT2 inhibitors) can help adults with sepsis, a life-threatening response to infection. If you have new-onset sepsis and can take oral medicine, you may be eligible.
Hong Kong, Hong KongAges 18 years+ - NCT04286399RecruitingPhase 4
Prevention trial for heart outcomes in people with type 2 diabetes
This Phase 4 trial studies an approach to help prevent heart problems in adults with type 2 diabetes who are at higher heart risk. It may help reduce future cardiovascular events by testing medications for safety and benefit in this group.
SingaporeAges 40 years+ - NCT06142474RecruitingPhase 3
SGLT2 inhibitors for heart failure patients during ventilator weaning
This trial tests a heart failure medication (SGLT2 inhibitor) to help people with heart failure who are on a breathing machine (ventilator) get better and come off the machine faster. It is for patients with a specific type of heart failure where the heart pumps weakly (EF ≤ 40%).
TaipeiAges 20 years+ - NCT07172971RecruitingPhase 1
SGLT2i drug for heart health in Duchenne muscular dystrophy
This trial tests if an SGLT2i medication can help protect heart function in people with Duchenne muscular dystrophy (DMD). The drug is already approved for other conditions, and researchers want to see if it can slow or prevent heart muscle damage.
Nashville, TennesseeAges 8–18 - NCT05770687Recruiting
Testing diabetes heart medicine soon after a heart attack
This study looks at how starting an SGLT2 inhibitor (a diabetes medicine) around the time of a heart attack affects heart outcomes and heart muscle changes over time. It may help you and your care team understand whether this timing is beneficial after a PCI procedure.
SeoulAges 19 years+ - NCT06838286Recruiting
Study of triple therapy for type 2 diabetes
This study looks at the safety and effectiveness of adding a third oral diabetes medicine to your current two-drug combination. It is for adults with type 2 diabetes whose blood sugar is not well controlled on metformin plus one other pill.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT02378805Recruiting
Alport syndrome registry to help delay kidney failure
This is a registry that collects information from people with Alport syndrome to better understand the disease and how to delay kidney failure. It may help researchers learn which factors and treatments are most important over time.
Göttingen, Lower SaxonyAges Any age - NCT07482943RecruitingPhase 4
Dapagliflozin for heart function after Fontan procedure
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Hong KongAges 12 years+ - NCT05029115Enrolling by invitation
SGLT2 pill study for atrial fibrillation with type 2 diabetes
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
Yangcheon, SeoulAges 20–80 - NCT07157475Recruiting
Blood vessel complications after leg artery procedures with SGLT2 inhibitors
This study looks at how a type of medicine called SGLT2 inhibitors (used for diabetes, kidney disease, or heart issues) affects blood vessel complications in people who have had a leg procedure to improve blood flow. It compares patients taking the medicine to those who are not.
Wroclaw, Lower Silesian VoivodeshipAges 18 years+ - NCT06291155RecruitingPhase 4
How SGLT2 inhibitors work in the kidneys for type 2 diabetes
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
Ann Arbor, MichiganAges 18–80 - NCT04899479RecruitingPhase 4
SGLT-2 inhibitor after heart attack to improve heart recovery
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
SeoulAges 18 years+ - NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80 - NCT07309094Recruiting
Effects of a diabetes drug on fat tissue in kidney disease
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
Valencia, ValenciaAges 18–90 - NCT07237451Recruiting
Heart and kidney study of SGLT2 inhibitors
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
IașiAges 18 years+ - NCT07214818RecruitingPhase 2/Phase 3
SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT07174687RecruitingPhase 2
SGLT2 inhibitor for geographic atrophy
This study tests an SGLT2 inhibitor (dapagliflozin) as a possible treatment for geographic atrophy, a progressive form of dry age-related macular degeneration that causes vision loss. It is for people who meet specific eye and health criteria.
St Louis, MissouriAges 50 years+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07038356RecruitingPhase 3
Continuing empagliflozin during heart failure hospitalizations
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Jena, ThuringiaAges 18 years+ - NCT06932081Recruiting
Study of SGLT2i in adults with congenital heart disease
This trial is a registry that follows adults with congenital heart disease who have started taking an SGLT2 inhibitor medication. The goal is to learn how well this treatment works for this group of patients.
Baltimore, MarylandAges 18 years+ - NCT06929169RecruitingPhase 2
SGLT2 inhibitor heart health study in dialysis patients
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
Buenos Aires, Buenos AiresAges 18–70 - NCT07614230RecruitingPhase 4
SGLT2 drugs and heart artery health in diabetes
This study tests whether a diabetes medication called SGLT2 inhibitors can slow the buildup of plaque in heart arteries. Researchers will use special CT scans to track changes in your coronary arteries over time.
Beijing, Beijing MunicipalityAges 18–78
Hear when a new SGLT2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sglt2 inhibitors?
- Yes. Clin2 currently lists 40 recruiting sglt2 inhibitors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sglt2 inhibitors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sglt2 inhibitors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.